MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)。

CAS No. : 885060-09-3

MCE 國際站：Filanesib

產(chǎn)品活性：Filanesib (ARRY-520) 是一種選擇性的，非競爭性的紡錘體驅(qū)動蛋白 (KSP) 抑制劑，對人 KSP 作用的 IC₅₀ 值為 6 nM。Filanesib 在體外能通過誘導(dǎo)自噬 (apoptosis) 導(dǎo)致細胞死亡。Filanesib 具有高效的抗增生活性。

研究領(lǐng)域：Cell Cycle/DNA Damage  |  Cytoskeleton  |  Apoptosis

作用靶點：Kinesin  |  Apoptosis

In Vitro: Filanesib induces mitotic arrest in multiple cell lines.
Filanesib exhibits anti-proliferative against a broad range of human and rodent tumor cell lines, including a variety of leukemias and solid tumors, with EC₅₀s between 0.4 nM and 14.4 nM.
Filanesib (0.001-0.1 nM; 36 hours) induces apoptosis in a dose-dependent manner in HeLa cells.
Filanesib (3.13-6.25 nM; 44 hours) causes accumulation of cells in the G2/M phase of the cell cycle in a dose-dependent manner in HeLa cells.
Filanesib potently induces cell cycle block and subsequent death in leukemic cells via the mitochondrial pathway and has potential to eradicate AML progenitor cells.
Filanesib (3 μM; 6-24 hours) is able to induce caspase-2 activation.
Filanesib (0.003-3 μM; 24-48 hours) is cytotoxic in Type II EOC cells.

In Vivo: Filanesib (20 mg/kg, 30 mg/kg; i.p.; q4dx3) has anti-tumor activitiy in vivo.

相關(guān)產(chǎn)品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Cytoskeleton Compound Library  |  Anti-Blood Cancer Compound Library  |  MG-132  |  LY294002  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Paclitaxel  |  Y-27632 dihydrochloride  |  Angiotensin II human  |  Acetylcysteine  |  SP600125  |  5-Fluorouracil  |  Staurosporine  |  Bortezomib  |  Tamoxifen  |  2-Deoxy-D-glucose  |  Gemcitabine  |  Verteporfin  |  Decitabine  |  Temozolomide  |  BAY 11-7082  |  Etoposide  |  DAPT  |  CCCP  |  Rotenone  |  Stattic  |  Etomoxir  |  Docetaxel  |  Fulvestrant  |  Everolimus  |  SB 202190

品牌介紹:
•   MCE (MedChemExpress) 擁有數(shù)百種全球獨家化合物，我們致力于為全球科研客戶提供最新最全的高品質(zhì)小分子活性化合物；
•   10,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng)域；
•   設(shè)有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥專利收錄了MCE客戶的科研成果；
•   專業(yè)團隊跟蹤最新的制藥及生命科學(xué)研究進展，為您提供全球最新的活性化合物；
•   與世界各大制藥公司及知名科研機構(gòu)建立了長期的合作。